News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
496,534 Results
Type
Article (9980)
Company Profile (157)
Press Release (486397)
Multimedia
Podcasts (16)
Webinars (7)
Section
Business (171332)
Career Advice (366)
Deals (26341)
Drug Delivery (15)
Drug Development (54247)
Employer Resources (23)
FDA (9937)
Job Trends (8955)
News (244180)
Policy (18384)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (591)
Accelerated approval (21)
ADA (21)
Adcomms (1)
Allergies (98)
Alliances (34426)
ALS (107)
Alzheimer's disease (1003)
Antibody-drug conjugate (ADC) (295)
Approvals (10520)
Artificial intelligence (348)
ASCO (166)
Autoimmune disease (213)
Automation (32)
Bankruptcy (269)
Best Places to Work (7141)
BIO (41)
BIOSECURE Act (3)
Biosimilars (124)
BioSpace Insights (27)
Biotechnology (99)
Bladder cancer (138)
Brain cancer (33)
Breast cancer (519)
Cancer (3755)
Cardiovascular disease (222)
Career advice (295)
Career pathing (2)
CAR-T (186)
CDC (2)
Celiac Disease (1)
Cell therapy (519)
Cervical cancer (38)
Clinical research (48781)
Collaboration (1343)
Commercialization (2)
Company closure (3)
Compensation (1410)
Complete response letters (35)
COVID-19 (887)
CRISPR (69)
C-suite (800)
Cystic fibrosis (89)
Data (5700)
Denatured (10)
Depression (110)
Dermatology (61)
Diabetes (351)
Diagnostics (4305)
Digital health (37)
Diversity (2)
Diversity, equity & inclusion (4)
Drug discovery (181)
Drug pricing (16)
Drug shortages (2)
Duchenne muscular dystrophy (182)
Earnings (73828)
Editorial (6)
Employer branding (4)
Employer resources (21)
Events (89169)
Executive appointments (738)
FDA (12545)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (1033)
Gene editing (142)
Generative AI (12)
Gene therapy (351)
GLP-1 (343)
Government (1058)
Grass and pollen (2)
Guidances (286)
Healthcare (9524)
Hematology (95)
HIV (54)
Huntington's disease (24)
IgA nephropathy (63)
Immunology and inflammation (133)
Immuno-oncology (68)
Indications (154)
Infectious disease (1089)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (88)
Intellectual property (255)
Interviews (46)
IPO (12584)
IRA (7)
Job creations (2142)
Job search strategy (281)
JPM (5)
Kidney cancer (19)
Labor market (12)
Layoffs (105)
Leadership (3)
Legal (5284)
Licensing (2)
Liver cancer (48)
Longevity (18)
Lung cancer (513)
Lymphoma (252)
Machine learning (30)
Management (7)
Manufacturing (558)
Marketing (7)
MASH (120)
Medical device (8737)
Medtech (8866)
Mergers & acquisitions (14776)
Metabolic disorders (740)
mRNA (61)
Multiple sclerosis (106)
NASH (4)
Neurodegenerative disease (234)
Neuropsychiatric disorders (47)
Neuroscience (1893)
NextGen: Class of 2026 (3339)
Non-profit (961)
Now hiring (15)
Obesity (245)
Opinion (30)
Ovarian cancer (160)
Pain (176)
Pancreatic cancer (207)
Parkinson's disease (207)
Partnered (14)
Patents (473)
Patient recruitment (504)
Peanut (32)
People (42830)
Pharmaceutical (31)
Pharmacy benefit managers (8)
Phase 1 (15896)
Phase 2 (21855)
Phase 3 (14726)
Pipeline (6957)
Policy (33)
Postmarket research (1581)
Preclinical (6722)
Press Release (34)
Prostate cancer (189)
Psychedelics (12)
Radiopharmaceuticals (197)
Rare diseases (605)
Real estate (3258)
Recruiting (10)
Regulatory (15123)
Reports (20)
Research institute (682)
Resumes & cover letters (52)
Rett syndrome (39)
RNA editing (8)
RSV (49)
Schizophrenia (108)
Series A (187)
Series B (137)
Service/supplier (4)
Sickle cell disease (64)
Special edition (3)
Spinal muscular atrophy (88)
Sponsored (6)
Startups (2293)
Stomach cancer (5)
Supply chain (52)
Tariffs (2)
The Weekly (6)
Vaccines (356)
Venture capital (36)
Weight loss (94)
Women's health (80)
Worklife (1)
Date
Today (3)
Last 7 days (367)
Last 30 days (1170)
Last 365 days (19839)
2026 (11562)
2025 (20029)
2024 (23650)
2023 (27247)
2022 (35556)
2021 (38269)
2020 (34515)
2019 (24053)
2018 (18182)
2017 (19408)
2016 (18579)
2015 (24851)
2014 (22088)
2013 (18611)
2012 (20710)
2011 (20867)
2010 (20709)
Location
Africa (250)
Alabama (75)
Alaska (2)
Arizona (301)
Arkansas (11)
Asia (19002)
Australia (2290)
California (11924)
Canada (3114)
China (567)
Colorado (474)
Connecticut (404)
Delaware (208)
Europe (27404)
Florida (1752)
Georgia (367)
Hawaii (4)
Idaho (47)
Illinois (709)
India (47)
Indiana (319)
Iowa (13)
Japan (399)
Kansas (109)
Kentucky (31)
Louisiana (27)
Maine (25)
Maryland (1180)
Massachusetts (7851)
Michigan (305)
Minnesota (560)
Mississippi (5)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (63)
New Jersey (2618)
New Mexico (12)
New York (2775)
North Carolina (1259)
North Dakota (4)
Northern California (5967)
Ohio (282)
Oklahoma (15)
Oregon (18)
Pennsylvania (2222)
Puerto Rico (21)
Rhode Island (31)
South America (424)
South Carolina (75)
South Dakota (1)
Southern California (4906)
Tennessee (119)
Texas (1918)
United States (38645)
Utah (355)
Vermont (1)
Virginia (153)
Washington D.C. (42)
Washington State (957)
West Virginia (2)
Wisconsin (84)
496,534 Results for "nielsen biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nielsen BioSciences Announces Positive Phase 3 Trial Results of CANDIN for the Treatment and Clearance of Common Warts
May 27, 2026
·
4 min read
Press Releases
Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd.
October 24, 2025
·
3 min read
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
July 27, 2026
·
2 min read
·
Tristan Manalac
Drug Development
Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts
Nielsen BioSciences, Inc. today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN ® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
March 5, 2024
·
3 min read
Press Releases
Nielsen BioSciences Successfully Completes Enrollment into Phase 3 Trial of CANDIN for the Treatment of Common Warts
February 26, 2025
·
3 min read
Press Releases
La Jolla Labs Inc., Unravel Biosciences Inc., and Ulm University Announce Strategic Collaboration to Advance AI-Driven Therapeutics for ALS
July 16, 2026
·
1 min read
Press Releases
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 13, 2026
·
3 min read
Business
Vial Partners with Nielsen BioSciences, Inc. in Phase III Clinical Trial for the Treatment of Common Warts
Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to study the safety and efficacy of CANDIN® for the treatment of common warts.
June 14, 2023
·
5 min read
Business
Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts
Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).
May 16, 2023
·
5 min read
Press Releases
NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences
July 1, 2026
·
7 min read
1 of 49,654
Next
